Thursday, January 09, 2025 9:23:45 AM
https://www.esperion.com/news-releases/news-release-details/esperion-host-virtual-key-opinion-leader-event-wednesday-january
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
January 9, 2025
PDF Version
Back to Newsroom
– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease –
ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe).
The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:
Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
Volume: | 3,093,362 |
Day Range: | 2.08 - 2.26 |
Bid: | 2.09 |
Ask: | 2.10 |
Last Trade Time: | 1:07:23 PM EST |
Total Trades: | 5,681 |
Recent ESPR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2025 09:38:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2025 09:37:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2025 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2025 08:17:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2025 01:40:37 PM
- Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. • GlobeNewswire Inc. • 01/09/2025 01:00:00 PM
- Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 09:14:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 09:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 09:12:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 12:10:59 PM
- Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions • GlobeNewswire Inc. • 12/18/2024 12:00:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/17/2024 08:46:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/17/2024 08:22:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/17/2024 08:21:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 11:43:14 AM
- Esperion Announces $210 Million Convertible Debt Financing • GlobeNewswire Inc. • 12/13/2024 11:00:00 AM
- Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel • GlobeNewswire Inc. • 12/12/2024 01:00:55 PM
- Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk • GlobeNewswire Inc. • 12/02/2024 01:00:00 PM
- Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia • GlobeNewswire Inc. • 11/26/2024 01:00:00 PM
- Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference • GlobeNewswire Inc. • 11/21/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2024 09:10:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/19/2024 09:07:29 PM
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 • GlobeNewswire Inc. • 11/18/2024 03:30:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 01:42:21 PM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM